Your browser is no longer supported. Please, upgrade your browser.
XOMA Corporation
Index- P/E227.99 EPS (ttm)0.15 Insider Own0.40% Shs Outstand11.24M Perf Week3.38%
Market Cap372.65M Forward P/E- EPS next Y-0.81 Insider Trans-93.77% Shs Float10.65M Perf Month5.14%
Income5.90M PEG12.00 EPS next Q-0.35 Inst Own60.90% Short Float3.41% Perf Quarter-9.20%
Sales29.00M P/S12.85 EPS this Y446.30% Inst Trans-0.04% Short Ratio12.85 Perf Half Y-6.32%
Book/sh7.27 P/B4.67 EPS next Y34.40% ROA5.60% Target Price52.33 Perf Year99.24%
Cash/sh6.18 P/C5.50 EPS next 5Y19.00% ROE9.60% 52W Range15.48 - 46.32 Perf YTD-23.02%
Dividend- P/FCF32.40 EPS past 5Y17.30% ROI13.00% 52W High-26.66% Beta0.90
Dividend %- Quick Ratio5.40 Sales past 5Y-11.90% Gross Margin- 52W Low119.44% ATR2.40
Employees10 Current Ratio5.40 Sales Q/Q-50.00% Oper. Margin40.20% RSI (14)54.85 Volatility6.48% 7.64%
OptionableNo Debt/Eq0.23 EPS Q/Q-44.20% Profit Margin20.30% Rel Volume1.58 Prev Close33.52
ShortableYes LT Debt/Eq0.14 EarningsMay 06 BMO Payout0.00% Avg Volume28.25K Price33.97
Recom2.00 SMA201.87% SMA506.81% SMA200-1.20% Volume44,757 Change1.34%
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-22-15Downgrade Ladenburg Thalmann Buy → Neutral
Oct-10-14Resumed ROTH Capital Buy $9
Apr-29-14Upgrade MLV & Co Hold → Buy $7
Mar-11-14Downgrade MLV & Co Buy → Hold $8 → $7
Mar-05-14Reiterated Ladenburg Thalmann Buy $6.50 → $10
Oct-31-13Reiterated MLV & Co Buy $7.50 → $8
May-09-13Reiterated Ladenburg Thalmann Buy $5 → $6
May-14-12Initiated Cowen & Co Outperform
Mar-31-11Reiterated MLV Capital Buy $12 → $10
Mar-23-11Reiterated RBC Capital Mkts Outperform $8 → $6
Jul-28-21 07:30AM  
Jul-15-21 06:38AM  
Jun-23-21 03:16PM  
Jun-21-21 07:30AM  
Jun-08-21 10:38AM  
May-21-21 08:00AM  
May-06-21 09:15AM  
May-03-21 07:30AM  
Apr-15-21 09:05AM  
Apr-12-21 07:30AM  
Apr-06-21 07:02PM  
Apr-05-21 04:05PM  
Mar-23-21 08:00AM  
Mar-22-21 07:30AM  
Mar-10-21 08:45AM  
Mar-03-21 05:16AM  
Mar-02-21 12:30PM  
Feb-23-21 04:05PM  
Jan-04-21 04:05PM  
Dec-30-20 05:50AM  
Dec-21-20 05:00PM  
Dec-10-20 11:45PM  
Dec-08-20 08:38AM  
Nov-16-20 07:30AM  
Nov-12-20 09:47AM  
Nov-11-20 07:30AM  
Nov-06-20 08:56AM  
Nov-05-20 09:35AM  
Nov-03-20 07:30AM  
Oct-28-20 07:30AM  
Oct-14-20 07:30AM  
Sep-23-20 12:15PM  
Sep-10-20 11:18AM  
Sep-02-20 07:30AM  
Aug-17-20 07:19AM  
Aug-06-20 07:50PM  
Aug-05-20 07:30AM  
Jul-28-20 12:33PM  
Jul-01-20 07:30AM  
Jun-29-20 07:30AM  
Jun-24-20 11:00PM  
Jun-22-20 01:58PM  
May-11-20 01:42PM  
May-05-20 09:45AM  
Apr-28-20 12:39PM  
Apr-27-20 12:31PM  
Mar-13-20 10:53AM  
Mar-10-20 07:30AM  
Mar-09-20 05:00AM  
Feb-27-20 12:30PM  
Feb-25-20 04:30PM  
Jan-22-20 01:02PM  
Dec-26-19 07:12AM  
Dec-23-19 04:00PM  
Dec-20-19 04:35PM  
Dec-16-19 09:34AM  
Dec-05-19 05:04PM  
Dec-02-19 04:30PM  
Nov-19-19 04:30PM  
Nov-13-19 06:47AM  
Nov-05-19 08:20AM  
Oct-30-19 10:33AM  
Oct-15-19 03:39PM  
Sep-27-19 07:56AM  
Sep-26-19 04:07PM  
Sep-12-19 01:37PM  
Sep-03-19 08:00AM  
Aug-13-19 08:30AM  
Aug-12-19 07:30AM  
Aug-06-19 10:05AM  
Jul-30-19 03:16PM  
Jul-09-19 02:07PM  
Jun-13-19 06:45AM  
Jun-07-19 09:25AM  
May-06-19 07:55PM  
May-01-19 10:33AM  
Apr-12-19 05:20PM  
Apr-11-19 12:14PM  
Apr-08-19 06:00AM  
Apr-03-19 07:00AM  
Mar-07-19 07:05AM  
Mar-05-19 07:00AM  
Feb-21-19 05:48PM  
Feb-13-19 07:00AM  
Feb-04-19 07:28AM  
XOMA Corporation, a biotech royalty aggregator, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action;. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; Takeda Pharmaceutical Company Limited; and Cadila Healthcare Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Neal James RCEOJun 25Sale33.629,027303,47411,822Jun 29 05:09 PM
BVF PARTNERS L P/ILDirectorMar 31Sale38.3681,9033,141,799149,975Apr 02 05:19 PM
BVF PARTNERS L P/ILDirectorMar 31Sale38.36569,79721,857,41375,287Apr 02 05:19 PM
VAN NESS W DENMANDirectorMar 15Option Exercise10.415,69959,33215,643Mar 16 04:30 PM
Neal James RCEODec 15Option Exercise5.5026,000143,00046,849Dec 17 04:30 PM
BURNS THOMAS M.SVP, Finance & CFODec 15Option Exercise4.0315,00060,45021,555Dec 17 04:30 PM
Neal James RCEODec 15Sale41.3526,0001,074,99820,849Dec 17 04:30 PM
BURNS THOMAS M.SVP, Finance & CFODec 15Sale41.4115,000621,0866,555Dec 17 04:30 PM
PERRY MATTHEW DSee Explanation of ResponsesDec 11Buy25.00200,0005,000,000200,000Dec 15 07:12 PM
BVF PARTNERS L P/ILDirectorDec 11Buy25.00200,0005,000,000200,000Dec 15 07:09 PM
Neal James RCEONov 23Option Exercise5.5013,12672,19333,975Nov 24 04:30 PM
BURNS THOMAS M.SVP, Finance & CFONov 23Option Exercise4.035,12520,65411,680Nov 24 04:30 PM
BURNS THOMAS M.SVP, Finance & CFONov 23Sale32.935,125168,7526,555Nov 24 04:30 PM
Neal James RCEONov 23Sale32.9613,126432,66220,849Nov 24 04:30 PM
Neal James RCEONov 20Option Exercise5.506,87437,80727,723Nov 24 04:30 PM
BURNS THOMAS M.SVP, Finance & CFONov 20Option Exercise4.036,87527,70613,430Nov 24 04:30 PM
BURNS THOMAS M.SVP, Finance & CFONov 20Sale32.526,875223,5556,555Nov 24 04:30 PM
Neal James RCEONov 20Sale32.526,874223,52320,849Nov 24 04:30 PM
Neal James RCEONov 05Option Exercise5.5010,00055,00030,849Nov 06 05:20 PM
BURNS THOMAS M.SVP, Finance & CFONov 05Option Exercise4.038,00032,24014,555Nov 06 05:20 PM
BURNS THOMAS M.SVP, Finance & CFONov 05Sale26.118,000208,9086,555Nov 06 05:20 PM
Neal James RCEONov 05Sale26.0210,000260,20520,849Nov 06 05:20 PM
BVF PARTNERS L P/ILDirectorSep 23Buy18.2017,089311,0162,040,124Sep 23 07:26 PM
BVF PARTNERS L P/ILDirectorSep 22Buy18.4511,951220,4452,030,236Sep 23 07:26 PM
BVF PARTNERS L P/ILDirectorSep 21Buy18.3922,328410,5032,023,276Sep 23 07:26 PM
BVF PARTNERS L P/ILDirectorSep 04Buy18.777,737145,2282,011,017Sep 10 08:10 AM
BVF PARTNERS L P/ILDirectorSep 01Buy18.8717,572331,5152,007,110Sep 01 08:37 PM
BVF PARTNERS L P/ILDirectorAug 31Buy18.4816,005295,7821,997,210Sep 01 08:37 PM
BVF PARTNERS L P/ILDirectorAug 28Buy19.172,04439,1871,988,067Sep 01 08:37 PM
BVF PARTNERS L P/ILDirectorAug 25Buy19.755,687112,2901,986,945Aug 25 08:10 PM
BVF PARTNERS L P/ILDirectorAug 24Buy19.3111,683225,5911,983,502Aug 25 08:10 PM
BVF PARTNERS L P/ILDirectorAug 21Buy19.3210,805208,7701,976,998Aug 25 08:10 PM
BVF PARTNERS L P/IL10% OwnerAug 20Buy19.121,77233,8811,967,800Aug 20 06:56 PM
BVF PARTNERS L P/IL10% OwnerAug 19Buy19.703,49668,8771,966,028Aug 20 06:56 PM
BVF PARTNERS L P/IL10% OwnerAug 18Buy19.2789517,2461,962,532Aug 20 06:56 PM
BVF PARTNERS L P/IL10% OwnerAug 14Buy18.6921,922409,8101,961,637Aug 14 06:38 PM
BVF PARTNERS L P/IL10% OwnerAug 13Buy17.801,05018,6931,939,715Aug 14 06:38 PM
BVF PARTNERS L P/IL10% OwnerAug 12Buy17.344,05070,2331,938,665Aug 14 06:38 PM